Results 1 to 10 of about 35,110 (238)
The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells
BMC Cancer, 2011 Background Chondrosarcoma is virtually resistant to chemotherapy and radiation therapy. Survivin, the smallest member of the inhibitor of apoptosis protein family, is a critical factor for tumor progression and resistance to conventional therapeutic ...
Grifka Joachim +6 more
doaj +5 more sources
Molecular Cancer, 2010 Background Chondrosarcoma is a disease that does not respond to conventional cytotoxic chemotherapy and expression of MMP1 is a marker for a poor prognosis. The mechanism of increased MMP1 expression in chondrosarcoma is not completely known. Our goal is
Lei Wei, Qian Chen, Richard M Terek
exaly +3 more sources
Cyclooxygenase-2 enhances α2β1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells [PDF]
Molecular Cancer, 2010 Background Cyclooxygenase (COX)-2, the inducible isoform of prostaglandin (PG) synthase, has been implicated in tumor metastasis. Interaction of COX-2 with its specific EP receptors on the surface of cancer cells has been reported to induce cancer ...
Ju-Fang Liu, Chih-Hsin Tang
exaly +3 more sources
BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumors [PDF]
BMC Cancer, 2012 Background As major regulators of normal chondrogenesis, the bone morphogenic protein (BMP) and transforming growth factor β (TGFB) signaling pathways may be involved in the development and progression of central chondrosarcoma. In order to uncover their
Boeuf Stephane +6 more
doaj +2 more sources
Description of the immune microenvironment of chondrosarcoma and contribution to progression
OncoImmunology, 2017 Chondrosarcoma (CHS) is a rare bone malignancy characterized by its resistance to conventional systemic and radiation therapies. Whether immunotherapy targeting immune checkpoints may be active in these tumors remains unknown.
Christophe Caux
exaly +2 more sources
EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression
eLife, 2023 Chondrosarcomas are primary cancers of cartilaginous tissue and capable of alteration to highly aggressive, metastatic, and treatment-refractory states, leading to a poor prognosis with a five-year survival rate at 11 months for dedifferentiated subtype.
Zong-Shin Lin +11 more
doaj +1 more source
Proteomes, 2022 Chondrosarcoma is the second most common bone tumor, accounting for 20% of all cases. Little is known about the pathology and molecular mechanisms involved in the development and in the metastatic process of chondrosarcoma. As a consequence, there are no
Donatella Pia Spanò +8 more
doaj +1 more source
Cell Death and Disease, 2022 Chondrosarcoma (CHS) is a rare type of soft sarcoma with increased production of cartilage matrix arising from soft bone tissues. Currently, surgical resection is the primary clinical treatment for chondrosarcoma due to the poor response to radiotherapy ...
Yang Li +3 more
doaj +1 more source
Cells, 2022 New treatments for chondrosarcoma are extremely important. Chondrosarcoma is a primary malignant bone tumor with a very unfavorable prognosis. High-grade chondrosarcoma has a high potential to metastasize to any organ in the body. Platelet-derived growth
Chang-Yu Song +9 more
doaj +1 more source
Mesenchymal chondrosarcoma of the mandible: A case report
Journal of Craniomaxillofacial Research, 2021 Mesenchymal chondrosarcoma as an aggressive type of chondrosarcoma shows a characteristic biphasic histopathologic pattern. The head and neck region is included a high proportion of extra skeletal sites. Very rare examples of Mesenchymal Chondrosarcoma
Samira Derakhshan +3 more
doaj +1 more source